image dons

I make a donation


Efficiency of flecainide to prevent AF occurence after PFO closure

En cours

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

logo étude


To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.

date de réalisation


nombre de patients


nombre de centres participants

16 French sites

type de financement

Private (Fonds de Dotation Action & Abbott)


à venir

Assessment of Flecainide to Lower the patent foramen Ovale closure risk of Atrial fibrillation or Tachycardia : AFLOAT study

About 30% of ischemic strokes are cryptogenic. Patent Foramen Ovale (PFO) is present in about 25% of the general population. In cryptogenic strokes, PFO has been shown to be overrepresented and recent intervention studies have confirmed that PFO has a causal link with stroke.
In patients with recent cryptogenic stroke, these randomized studies have shown at least 50%-reduction of recurrent neurological events after PFO percutaneous closure compared with medical therapy alone. At the same time, authors identified a higher rate of newly-detected atrial arrhythmias after PFO closure than in medical treatment group. In a recent meta-analysis, 6.6% of PFO closure patients group had a new-onset atrial fibrillation/atrial flutter versus 0.7% in the medical treatment group. Most atrial fibrillation (AF) cases occurred within 1 month after the procedure, a finding that suggests that the procedure itself induces AF. AF is often poorly tolerated and bares the risk of stroke in these patients. When it occurs antiarrhythmic and anticoagulant treatments are required.
The risk of AF reported in these studies in certainly largely underestimated as only symptomatic and recorded episodes of AF have been declared. Patients often report palpitations without a diagnosis of AF made on the ECG or a Holter. Long term ECG monitoring provides more accurate data on AF incidence.
Administration of flecainide has been shown to be effective in preventing AF and may be useful in preventing these AF episodes after PFO closure.
To our knowledge, there is no study assessing the efficacy of any antiarrhythmic drug in the prevention of AF after PFO closure. AFLOAT will be the first randomized study to possibly validate flecainide to prevent AF in these patients
Patients will be randomized into 3 groups :

  • Group 1 : Flecainide 6 months ;
  • Group 2 : Flecainide 3 months then no additional treatment ;
  • Group 3 : No additional treatment.

Autres études



En cours

Evaluation of Anakinra versus placebo in treatment of acute myocarditis and evaluation of the contuity of the reference treatment with IEC in patients without ventricular dysfunction ventriculaire.


En cours

Phase 4 trial, evaluating the interest of betablocking treatment in the long term treatment of non-complicated myocardial infarct.


En cours

Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.